3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Interventions
Imatinib Mesylate
28
nilotinib
21
Cytarabine
21
Methotrexate
16
Hydroxyurea
15
Cyclophosphamide
15
Busulfan
15
Peripheral Blood Stem Cell Transplantation
13
ruxolitinib
11
Etoposide
11
Whole-Body Irradiation
10
fludarabine phosphate
9
fludarabine
9
Tacrolimus
9
Mycophenolic Acid
9
Daunorubicin
9
Idarubicin
8
Radiotherapy
7
Mitoxantrone
7
Interferon-alpha
7
Cyclosporine
6
peginterferon alfa-2a
5
bosutinib
5
asciminib
5
Melphalan
5
Azacitidine
5
merphos
4
luspatercept
4
Thioguanine
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
N(4)-oleylcytosine arabinoside
×
Myeloid
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled